International consensus on clinical use of presynaptic dopaminergic positron emission tomography imaging in parkinsonism
- 4 October 2023
- journal article
- research article
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 51 (2) , 434-442
Abstract
Purpose Presynaptic dopaminergic positron emission tomography (PET) imaging serves as an essential tool in diagnosing and differentiating patients with suspected parkinsonism, including idiopathic Parkinson’s disease (PD) and other neurodegenerative and non-neurodegenerative diseases. The PET tracers most commonly used at the present time mainly target dopamine transporters (DAT), aromatic amino acid decarboxylase (AADC), and vesicular monoamine type 2 (VMAT2). However, established standards for the imaging procedure and interpretation of presynaptic dopaminergic PET imaging are still lacking. The goal of this international consensus is to help nuclear medicine practitioners procedurally perform presynaptic dopaminergic PET imaging. Method A multidisciplinary task group formed by experts from various countries discussed and approved the consensus for presynaptic dopaminergic PET imaging in parkinsonism, focusing on standardized recommendations, procedures, interpretation, and reporting. Conclusion This international consensus and practice guideline will help to promote the standardized use of presynaptic dopaminergic PET imaging in parkinsonism. It will become an international standard for this purpose in clinical practice.Keywords
Funding Information
- Dream Project of Ministry of Science and Technology of the People's Republic of China (2021YFA1101700)
This publication has 47 references indexed in Scilit:
- Dopamine transporter imaging for the diagnosis of dementia with Lewy bodiesCochrane Database of Systematic Reviews, 2015
- Correlation of Parkinson Disease Severity and18F-DTBZ Positron Emission TomographyJAMA Neurology, 2014
- In Vivo Detection of Monoaminergic Degeneration in Early Parkinson Disease by 18F-9-Fluoropropyl-(+)-Dihydrotetrabenzazine PETJournal of Nuclear Medicine, 2013
- Longitudinal evolution of compensatory changes in striatal dopamine processing in Parkinson's diseaseBrain, 2011
- Dopamine Transporter SPECT Imaging in Corticobasal SyndromePLOS ONE, 2011
- In Vivo Measurement of Vesicular Monoamine Transporter Type 2 Density in Parkinson Disease with 18F-AV-133Journal of Nuclear Medicine, 2010
- Dopaminergic function and progression of Parkinson's disease: PET findingsParkinsonism & Related Disorders, 2009
- Longitudinal progression of sporadic Parkinson's disease: a multi-tracer positron emission tomography studyBrain, 2009
- 18F-FP-CIT PET imaging and SPM analysis of dopamine transporters in Parkinson’s disease in various Hoehn & Yahr stagesJournal of Neurology, 2007
- An [18F]dopa–PET and clinical study of the rate of progression in Parkinson’s diseaseBrain, 1996